News
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...
Let's look at why this news could be a game-changer for Eli Lilly and its stock.
Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results